Document is current

Article History

Accepted: 29 January 2025

First Online: 5 February 2025

Declarations

:

: The clinical study and analyses in this report were supported by Alzheon, Inc.

: John A. Hey, Jeremy Y. Yu, Susan Abushakra, Jean F. Schaefer, Aidan Power, Patrick Kesslak, Jijo Paul and Martin Tolar are employees of Alzheon, Inc. All authors own Alzheon stocks and/or stock options.

: The protocol was approved by the assigned Ethics Committees (EC) in the Netherlands and in Czech Republic and by the institutional EC in the Czech Republic. These include the Medical-Ethical Review Committee (METC), 12 October 2020; Ethics Committee of the Fakultní nemocnice Brno, 14 October 2020; Ethics Committee of the Fakultní nemocnice v Motole, 09 September 2020; Ethics Committee of the Fakultní nemocnice u sv Anny v Brne, 09 September 2020; and Etická Komise Vestra Clinics, 17 September 2020.

: All subjects and their partners, caregivers or legal representatives signed informed consent before participation in the study.

: All subjects and their partners, caregivers or legal representatives provided consent that the data are publishable before participation in the study.

: The data and material contained in this publication are proprietary to Alzheon Inc.

: Not applicable.

: JAH wrote the article in collaboration with JYY and JFS; SA, JAH, AP, PK, JP and MT were involved in the design and conduct of the ALZ-801-201 ADBM study. All authors have read and approved the final submitted manuscript and agree to be accountable for the work.